Page last updated: 2024-12-08
parkeol
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Description
parkeol: the triterpene precursor of saponins in sea cucmbers; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
parkeol : A tetracyclic triterpenoid comprised of a lanostane skeleton which is 3beta-hydroxylated and has double bonds at the 9(11)- and 24-positions. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 12313974 |
| CHEBI ID | 63460 |
| MeSH ID | M0247430 |
Synonyms (16)
| Synonym |
|---|
| parkeol |
| 514-45-4 |
| C19918 |
| lanosta-9(11),24-dien-3beta-ol |
| 5alpha-lanosta-9(11),24-dien-3beta-ol |
| delta(9(11),24)-lanostadien-3beta-ol |
| 4,4,14alpha-trimethyl-5alpha-cholesta-9(11),24-dien-3beta-ol |
| CHEBI:63460 |
| DTXSID20487430 |
| (3s,5r,8s,10s,13r,14s,17r)-4,4,10,13,14-pentamethyl-17-[(2r)-6-methylhept-5-en-2-yl]-2,3,5,6,7,8,12,15,16,17-decahydro-1h-cyclopenta[a]phenanthren-3-ol |
| Q27132633 |
| lanosta-9(11),24-dien-3-ol, (3b)- |
| lanosta-9(11),24-dien-3-ol, (3beta)- |
| FM88E87P32 |
| (3beta)-lanosta-9(11),24-dien-3-ol |
| (3s,5r,8r,10r,13r,14r,17r)-4,4,10,13,14-pentamethyl-17-((2r)-6-methylhept-5-en-2-yl)-2,3,5,6,7,8,12,15,16,17-decahydro-1h-cyclopenta(a)phenanthren-3-ol |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Roles (1)
| Role | Description |
|---|---|
| metabolite | Any intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Drug Classes (3)
| Class | Description |
|---|---|
| 3beta-sterol | A sterol in which the hydroxy group at position 3 has beta- configuration. |
| tetracyclic triterpenoid | Any triterpenoid consisting of a tetracyclic skeleton. |
| 3beta-hydroxy-4,4-dimethylsteroid | Any 3beta-hydroxy steroid which is substituted by two methyl groups at position 4. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Pathways (1)
| Pathway | Proteins | Compounds |
|---|---|---|
| parkeol biosynthesis | 1 | 2 |
Research
Studies (6)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||